6 news items
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
ATOS
29 Apr 24
Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as "expect," "potential," "continue," "may
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
ATOS
15 Apr 24
of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as "expect
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
ATOS
9 Apr 24
Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as "expect," "potential," "continue," "may
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
ATOS
1 Apr 24
the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as "expect
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
ATOS
12 Mar 24
Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as "expect," "potential," "continue," "may
nuxuwqs50llv
ATOS
22 Feb 24
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking
- Prev
- 1
- Next